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Abstract
Paracetamol is used widely in pediatrics because it has a high drug safety when used in therapeutic dosages. In
case of overdose the majority of paracetamol is metabolized to N-acetyl-p-benzoquinone imine (NAPQI), which is
responsible for the severe toxic effects. The covalent connection between NAPQI and hepatic proteins leads to
hepatocellular damage and possibly to severe liver failure. The antidote for paracetamol is N-acetylcysteine (NAC). It
is a precursor of glutathione and aids to fill glutathione stores. The Rumack-Matthew nomogram should be used to
decide on antidote treatment. Pediatric drug metabolism differs from adult metabolism. Children have a larger liver
size compared to their body weight than adults, resulting in a higher metabolism rate. Young children seem to be
less sensitive to acute intoxication than adults. One hypothesis to explain the lower rate refers to the larger liver
size. The acute toxic dosage for children is more than 200 mg/kg body weight. There seems to be a global increase
in accidental pediatric paracetamol overdose. Governmental websites of various European Union (EU) countries
were searched for legal information on paracetamol availability in pharmacies and non-pharmacy stores. Various
EU countries permit prescription-free sales of paracetamol in pharmacies and non-pharmacy stores. In Sweden
paracetamol 500 mg may be sold in both pharmacies and non-pharmacies in a maximum pack size of 20 units. In
the United Kingdom (UK) paracetamol 500 mg is listed in the general sales list with a maximum pack size of 30
effervescent tablets or 16 tablets. In Ireland paracetamol 500 mg may be sold in a maximum pack size of 12 units
in a non-pharmacy. In the Netherlands paracetamol 500 mg is legal to be sold in a maximum pack size of 50 units
in a drug store and with a maximum of 20 units in any other non-pharmacy. Several countries in the European
Union are permitted to offer paracetamol prescription-free in pharmacies and non-pharmacy stores without legal
guidance on the storage position within the store. Further research is needed to investigate whether paracetamol
is located directly accessible to young children within the stores in EU countries which permit prescription-free
sales of paracetamol.
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Background
Paracetamol is an important drug against pain and fever.
It is highly popular and used worldwide. Paracetamol
has a high drug safety when used in recommended
dosages. In the United States of America (US) approxi-
mately 50 million adults consume paracetamol containing
products every week. Nevertheless, an overdose can lead
to severe liver failure [1]. The substance is named differ-
ently throughout the world; in the US and Canada the
name acetaminophen is mostly used. In other countries
like Germany, the UK or Australia it is called paracetamol.
Both names have their origin from the labeling of the
chemical structure [2] (Fig. 1). This narrative review sum-
marizes the effects of paracetamol intoxication, especially
in children. Additionally, it outlines the current legal re-
quirements on paracetamol sales in various countries of
the European Union in order to establish whether the
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pharmaceutical might be accessible to young children
within pharmacies and non-pharmacy stores.
Pharmacological differences between children
and adults
Some fundamental pharmacological effects differ between
children and adults. Additionally, differences occur be-
tween the diverse pediatric age groups. Table 1 provides
an overview of age subdivision in pediatric population.
The largest variations exist between neonates and adults.
Drug absorption depends on assimilation route and bio-
chemical drug characteristics. Most pharmaceuticals in
pediatrics are administered orally and therefore gastric pH
and gastrointestinal motility are important. Drug absorp-
tion does not seem to differ significantly between infants,
older children or adults [3, 4]. Metabolism of a drug is
often dependent on the liver. Metabolism rate depends on
two factors: the size of the liver and the effectiveness of
enzymes. Children have a much larger liver size compared
to their body weight than adults; liver volume relative to
body weight is twice as high in a child aged 1 year than in
a child aged 14 years. Subsequently, children have a higher
metabolism rate than adolescents and adults. One excep-
tion is neonates as their enzyme production capacity is
still immature and cannot function as effectively yet. Renal
elimination is an important way of drug elimination.
Tubular secretion and reabsorption are immature at birth,
but they reach maturity during the first year of life and
achieve adult capacities [3, 4].
Paracetamol toxicity
A US study from 2011 showed that both intentional and
accidental paracetamol poisoning continues to be a
major public health problem [5]. Paracetamol-induced
hepatotoxicity is the most common cause of liver failure
in the US [6]. In adults it was demonstrated that self-
treatment with paracetamol containing pharmaceuticals
can lead to unintentional poisoning [7]. According to
the pharmacologist K. Brune paracetamol belongs to the
most hazardous substances throughout the whole world
[8]. The hepatotoxic effect of paracetamol was first
described in 1966 by D.G. Davidson and W.N. Eastham.
They reported on two patients who had died of fulmin-
ate liver necrosis in the centrilobular areas after para-
cetamol overdose. Since then numerous studies have
emphasized the hepatic toxicity of this substance [1].
Paracetamol is metabolized via three different pathways:
conjugation with sulfate, conjugation with glucuronide
and transformationwith the cytochrome P450 enzyme sys-
tem to the highly active metabolite N-acetyl-p-benzo-
quinone imine (NAPQI) [9]. The metabolite NAPQI is
responsible for the severe toxic effects. When used in
therapeutic dosage paracetamol is mainly metabolized
via the first two pathways; only 5 % of the substance is
transformed to NAPQI [9]. NAPQI is immediately con-
jugated with reduced glutathione to form a hazard-free
metabolite [10]. However, in case of overdose the first
two pathways become saturated and the majority of
paracetamol is metabolized to NAPQI. The conjugation
between NAPQI and glutathione leads to a decrease of
glutathione stores. Subsequently, reduced glutathione
cannot be reestablished as efficiently as it is needed to
transform NAPQI into a harmless metabolite. High
amounts of NAPQI remain unbound which results in
covalent binding between free NAPQI and hepatic pro-
teins. This covalent connection leads to hepatocellular
damage [11].
Four stages of paracetamol intoxication are described
(Table 2) [11, 12]. At stage one, symptoms occur shortly
after poisoning and are unspecific. They often include
nausea, vomiting and malaise. After one to two days the
initial clinical findings diminish, but abdominal pain
may occur. In this stage abnormal laboratory values are
often observed, including elevated liver enzymes, in-
creased bilirubin and prolonged prothrombin time. Stage
three consists of the reappearance of initial unspecific
symptoms. In addition, liver function parameters reach
high abnormalities. Stage four occurs within the follow-
ing four to fourteen days; during this time the outcome
of the intoxication will appear. The patient will either
Fig. 1 Chemical structure of paracetamol, also known as N-acetyl-
p-aminophenol, modified after [39]
Table 1 Subdivision of pediatric population in age groups,
modified after [40]
Pediatric group Age
Neonates Birth to 1 month
Infants 1 month – 2 years
Young Children - Preschool 2 years – 6 years
Older Children - School 6 years – 12 years
Adolescents 12 years – 18 years
Table 2 Stages of paracetamol intoxication, modified after [11, 12]
Stage Time frame Symptoms
1 0.5 – 24 h Unspecific symptoms likediarrhea, nausea, malaise
2 24 – 48 h Abdominal pain,abnormal laboratory values
3 3 – 4 days Peak of hepatic dysfunction,stage 1 symptoms
may reappear
4 4 – 14 days Recovery or complete liver failure
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recover or develop complete liver failure [11]. Even
though it is uncommon, cases of acute renal failure
without the development of liver failure have been
reported [13, 14].
Paracetamol intoxication in children
Paracetamol is the most widely used medication in
pediatrics against pain or fever [11]. It is administered in
all pediatric age groups from premature neonatal pa-
tients to adolescents. For adult usage it is often pro-
duced in blister package containing 500 mg tablets. For
children various application methods and strengths exist
[15, 16]. Three main ways of ingestion lead to paraceta-
mol intoxication in children; deliberate overdose, unin-
tentional exposure or administration error [17]. Because
of its popularity in pediatrics, children are frequently
used to taking the drug. Adult and children paracetamol
medication is often stored at home and might be easily
available for children, risking the possibility for uninten-
tional poisoning in children by ingesting the pharma-
ceutical [11].
The acute toxic dosage for children appears to be
more than 200 mg/kg body weight. In case of repeated
dosage, intoxication seems to occur after application of
more than 75 mg/kg body weight a day in children
younger than 6 years of age. Acute toxic dose in adoles-
cents is considered to be more than 7.5 g in a single
dose [11, 18], even though in different ethical groups like
Japanese lower doses might already lead to intoxication
[19]. Nevertheless, children seem to be less sensitive to
acute intoxication than adults. One hypothesis to explain
the lower rate of severe intoxication in children in com-
parison to adults refers to their larger liver size in rela-
tion to body weight. Subsequently, children are probably
able to metabolize paracetamol more effectively than
adults because of larger glutathione stores [20].
The real incidence of liver failure in pediatric patients
due to paracetamol intoxication remains uncertain. A
Spanish study researched the incidence of oral antipyr-
etic poisoning in children up to 14 years. Out of all
cases, 11 % occurred due to paracetamol poisoning of
which 9.4 % were severe [21]. The US and the UK report
paracetamol intoxication to be the main cause of
pediatric liver failure, accounting for 14 % of all cases.
Most of these poisonings are due to intentional overdose
in adolescents, but there seems to be a global increase in
accidental overdose in children [17].
Treatment of acute paracetamol intoxication
Immediate identification of patients with acute paraceta-
mol intoxication is essential to reduce morbidity and
mortality [12]. Activated charcoal should be adminis-
tered instantly after acute ingestion [22]. The antidote
for paracetamol is N-acetylcysteine (NAC). It is a
precursor of glutathione and aids to fill glutathione
stores; full glutathione stores prevent the reaction of un-
bound NAPQI with hepatic cells. It does not affect the
paracetamol concentration or its elimination. It is im-
portant for the treatment to start as soon as possible
after poisoning [11]. The Rumack-Matthew nomogram
should be used to decide on antidote treatment (Fig. 2).
The nomogram was first established by B.H. Rumack
and H.Matthew on basis of a retrospective study of 64
cases of acute paracetamol ingestion. It exhibits the cor-
relation between paracetamol blood concentration and
hepatocellular injury. Hepatic toxicity is predicted in pa-
tients with paracetamol blood concentration at or above
a threshold line between 200 and 6.25 μg/ml 24 h post
ingestion. After the nomogram was introduced in the
US, the US Food and Drug Administration (FDA)
insisted on lowering the treatment threshold by 25 % for
safety reasons. Consequently, a line between 150 and
4.7 μg/ml 24 h post ingestion is considered as the treat-
ment threshold. NAC therapy should be initiated in pa-
tients with paracetamol levels at or above this threshold
[12]. Paracetamol concentration should be determined
from 4 h on after ingestion. Measurements prior to this
time frame may not reveal peak concentration and
therefore might be incorrect [11].
NAC has a high benefit. The antidote treatment is
considered efficient as it reduces the mortality to <0.5 %
even after serious hepatotoxicity. The effectiveness of
NAC therapy is not reduced by the hours passed after
poisoning or the heaviness of symptoms. Different
concepts exist on NAC therapy; two main protocols
recommend a 20-h intravenous treatment or a 72-h
oral treatment. Both approaches are well studied and
considered effective and safe. Oral administration may
irritate the gastrointestinal tract and can lead to
vomiting; it should be a patient specific choice which
method of application to use. Liver transplantation is
the only option left if NAC treatment failed in pa-
tients with severe hepatic injuries after paracetamol
intoxication [11, 12, 23].
Pharmaceutical legislation in European Union
countries
European Union countries receive legislation from two
different legislative authorities. On the one hand, na-
tional governments enact laws which apply to every dis-
tinct country individually. On the other hand, laws in
EU countries can be enacted by the EU. The European
Commission (EC), the European Parliament (EP) and
the European Council form the EU legislative body. The
EC proposes legislation which is discussed and eventu-
ally enacted by the EP and the European Council. Two
different types of legislation are performed by the EU:
regulations and directives. An EU regulation is instantly
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enforced as law in all EU member country at the same
time; it excels national law. EU directives are guidelines
with a defined goal and time period in which it has to be
incorporated into national law. Legislation processes on
EU level are complicated; occasionally it takes long time
until a regulation or directive becomes enforced [24–26].
The EU pharmaceutical law consists of diverse regulations
and directives concerning numerous pharmaceutical sub-
jects like pharmacovigilance, falsified medical products,
drug marketing and regulatory processes. Accessibility of
the pharmaceuticals paracetamol however is not regulated
by European law but by national law [27]. For this narra-
tive review governmental websites of various EU countries
were searched in order to analyze legal information on
paracetamol availability in pharmacies and non-pharmacy
stores. Four countries which have been part of the EU be-
fore 1995 were selected. Sweden was chosen as a Scandi-
navian country. Both Ireland and the UK were chosen due
to their proximity on the British Isles. The Netherlands
represent a Benelux country. The aim was to represent a
cultural variety within Western European countries.
Legislation in Sweden
The Swedish Medicines Act enables the Medical Product
Agency to control and monitor medical items in Sweden.
The agency is furthermore entitled to classify drugs
into prescription-free and prescription-only medica-
tion [28, 29]. Purchase without prescription is allowed
for paracetamol under certain circumstances (Table 3).
Paracetamol is allowed to be sold prescription-free in
strength of 20 units of 500 mg in both pharmacies
and non-pharmacies [30].
Legislation in the United Kingdom
The Medicines and Healthcare Products Regulatory
Agency is an administrative body of the British Depart-
ment of Health; this agency is responsible for admission,
monitoring and safety of pharmaceuticals in the United
Kingdom. The Medicines Act from 1968 constitutes the
legislation of pharmaceuticals. Medicines are divided
into three different categories:
 Prescription-only medication
 Pharmacy sales medication
 General sales list medication (GSL)
Certain requirements in package size and strength
apply for paracetamol in order to be listed as GSL
(Table 4). Maximally 30 effervescent tablets (TEF) or
16 tablets (tab) or capsules of paracetamol 500 mg may
be offered in non-pharmacy stores [31, 32].
Fig. 2 Rumack-Matthew nomogram, modified after [11]
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Legislation in Ireland
The Irish Medicines Board forms the official agency of
the Department of Health and Children. This agency
regulates pharmaceutical matters like drug safety, drug
risks and drug monitoring. The Medical Product
Regulations Law regulates prescription and supply of
pharmaceuticals. Three categories for medication exist
in Ireland. Pharmaceuticals are either classified as:
 General sales medication
 Prescription-controlled medication from schedule
1 (S1)
 Exemption from S1 medication.
These exemptions are either pharmaceuticals listed in
schedule 2 (S2) or S1 pharmaceuticals which are labeled
with maximum dose, maximum daily dose or maximum
treatment period. Paracetamol availability is regulated
with particular restrictions in Ireland; caution declara-
tions must appear on the package to give warning of
overdose. It is only allowed to purchase one single pack-
age at a time. In certain maximum strengths and pack-
age sizes paracetamol is available in non-pharmacy
stores [33–35] (Table 5).
Legislation in the Netherlands
The Dutch medicine law came into effect in 2007
and was enforced by the Ministry of National
Health, Wellbeing and Sports. This ministry instructs
the administrative body Medicines Evaluation Board
to control pharmaceutical safety and quality. Medica-
tions are divided into four different categories in the
Netherlands [36]:
 Prescription-only medication (UR)
 Pharmacy-only medication (UA)
 Pharmacy or drug store-only (UAD)
 Open sales medication (AV)
Paracetamol differs in classification according to
strength and application form (Table 6). Paracetamol
has AV status until a package size of 20 tablets of
500 mg and subsequently can be sold in any shop.
Package sizes of 20 – 50 tablets of 500 mg have
UAD status and may only be sold in drug stores or
pharmacies [37, 38].
Conclusions
Paracetamol is a drug which is widely used in
pediatrics. Severe intoxication in children seems to
be less frequent compared with adults. Nevertheless,
paracetamol poisoning can lead to liver failure with
possible fatal development in children. Several coun-
tries in the European Union are permitted to offer
paracetamol prescription-free in pharmacies and
non-pharmacy stores without legal guidance on the
storage position within the store. If the pharmaceut-
ical is placed openly and within the direct reach of a
child within the store, the infant or young child
might easily grab the package. This could lead to ac-
cidental poisoning if the child swallows the content.
Additionally, storing the pharmaceuticals in an un-
safe location in a public store might downplay the
danger of accidental poisoning and may mislead
parents or caregivers to also store the drugs in an
unsafe location at home. Accordingly, further investi-
gation is needed to analyze whether the pharmaceut-
ical is placed in direct accessibility to infants and
young children within these stores.




Pack sizenon-pharmacy Pack size
pharmacy
Tablet 250 mg 20 units 20 units
Tablet 500 mg 20 units 20 units
Oral solution 24 mg/ml 100 ml 100 ml
Suppository 500 mg 10 units 10 units
Table 4 Requirements for paracetamol to be listed GSL in the
UK, modified after [32]
Application form Dosage per unit Pack size
Tablet or capsules 500 mg (adults)
120 mg (children)
16 tablets or capsules
30 effervescent
tablets
Powders or granules 1000 mg (adults)
240 mg (children)
10 units
Liquids 5 % 160 ml
Table 6 Classification of paracetamol in the Netherlands,
modified after [38]
Application form Dosage per unit Pack size Status
Tablet 500 mg 20 tab Open sale medication
Tablet 500 mg 20 – 50 tab Pharmacy or drug
store only
Suppository 1000 mg 10 units Open sale medication







Tablet/capsule/sachet 500 mg 12 units 24 units
Tablet/capsule/sachet 600 mg 10 units 20 units
Tablet/capsule/sachet 1000 mg 6 units 12 units
Liquid 50 mg/ml 60 ml 240 ml
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